Funding Opportunity PAR-24-326 from the NIH Guide for Grants and Contracts. The Basic Instrumentation Grant (BIG) Program encourages applications from groups of NIH-supported investigators to purchase a single piece of new, costly, specialized, commercially available instrument or an integrated instrumentation system. The BIG Program is limited to institutions that have not received S10 instrumentation funding of $500,001 or greater in any of the preceding 3 Federal fiscal years (FY). Use the following to determine applicable funding periods: for submission in CY 2026, consider S10 funding in FYs 2023-2025; for submission in CY 2027, consider S10 funding in FYs 2024-2026; for submission in CY 2028, consider S10 funding in FYs 2025-2027. The minimum award is $25,000. There is no maximum price limit for the instrument; however, the maximum award is $350,000. Instruments supported include, but are not limited to, basic cell sorters, confocal microscopes, ultramicrotomes, gel imagers, or computer systems.

Notice NOT-HS-25-007 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-008 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-006 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-007 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-25-027 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) from the National Institute on Aging (NIA) invites applications on T1 translational aging research (i.e., bench to bedside) which focus on advancing new therapeutics from preclinical stages to first-in-human (FIH) trials for aging-related conditions such as sarcopenia, heart failure with preserved ejection fraction (HFpEF), and deficits such as immunosenescence. The NOFO will specifically support two categories of milestone-driven projects: 1) traditional de novo drug development (i.e., new chemical/molecular entities) with three specific entry points to the translational pipeline (i.e., screening through preclinical validation, hit to lead through IND, or late-stage preclinical development through FIH studies), and 2) data-driven computational drug repurposing strategies with subsequent validation of predictions and generation of proof-of-concept data in pertinent animal models and/or in human in vitro studies.For the purposes of this NOFO, drug repurposing (also known as drug repositioning, reprofiling or re-tasking) refers to approaches for identifying alternative uses for FDA-approved drugs or investigational therapeutics which are beyond the scope of the original intended clinical indication. The types and scale of proposed translational research activities in the projects are anticipated to vary and will depend on whether the project focuses on traditional drug development pathways or involves drug repurposing. The UG3 phase of this NOFO will support T1 translational research planning activities and preliminary studies. Transition to the UH3 phase (based on achievement of UG3 milestones proposed by the investigators) will enable more comprehensive pharmacology and/or toxicology evaluations of the proposed therapeutics, including replication studies to confirm preliminary findings or experimental validation of predictive models.

Funding Opportunity PAR-25-024 from the NIH Guide for Grants and Contracts. The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders. Although research supported by this FOA can include animal studies, it must also include preliminary human evaluation using carefully standardized human samples or datasets. The goal of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.

Notice NOT-OD-25-009 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-014 from the NIH Guide for Grants and Contracts

Notice NOT-HG-25-008 from the NIH Guide for Grants and Contracts

Notice NOT-TW-24-011 from the NIH Guide for Grants and Contracts

Notice NOT-AI-25-007 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-149 from the NIH Guide for Grants and Contracts. This limited competition Notice of Funding Opportunity (NOFO) invites renewal applications of existing NINDS-supported clinical trial cooperative agreement awards (U01) requiring additional time and resources to complete the clinical trial.

Notice NOT-AG-24-070 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-122 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to solicit applications for pilot projects to elucidate a role for understudied proteins in rare disease. Awards will support generation of preliminary data and/or tools around eligible understudied protein(s). A list of eligible proteins is provided and are members of druggable protein families that have a known association with a rare disease. This NOFO is intended to jumpstart research on understudied proteins that are associated with rare diseases and provide applicants with sufficient funding to perform basic biochemical and/or biological work to further the characterization of understudied proteins within the context of rare disease.

Notice NOT-HG-25-011 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-223 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) participating Institutes and Centers (ICs), in collaboration with the Global Alliance for Chronic Diseases (GACD), intends to publish Funding Opportunity Announcements (FOAs) to invite applications forimplementation research on noncommunicable diseases (NCDs) in World Bank-defined low- and middle-income countries (LMICs) and American Indian/Alaskan Native (AI/AN) Tribal Nation populations in the United States.

Funding Opportunity PAR-25-213 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) participating Institutes and Centers (ICs), in collaboration with the Global Alliance for Chronic Diseases (GACD), intends to publish Funding Opportunity Announcements (FOAs) to invite applications forimplementation research on noncommunicable diseases (NCDs) in World Bank-defined low- and middle-income countries (LMICs) and American Indian/Alaskan Native (AI/AN) Tribal Nation populations in the United States.

Notice NOT-OD-25-015 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-076 from the NIH Guide for Grants and Contracts. The Office of Research Infrastructure Programs (ORIP) encourages research project grant applications aimed at developing and implementing broadly applicable technologies, tools, and resources for validating animal models and enhancing rigor, reproducibility, and translatability of animal research. Research projects submitted under this Notice of Funding Opportunity (NOFO) should be hypothesis driven with strong preliminary data. Proposed studies, models, resources, or technologies under this NOFO must either address research interests of multiple NIH Institutes and Centers (ICs), explore multiple organ systems, or be applicable to diseases and processes that impact multiple organ systems in order to align with ORIPs NIH-wide mission and programs. Applications should aim to enhance the rigor, reproducibility, and translatability of animal research through the development and implementation of technologies, tools, and resources that have significant impact across a broad range of research areas using animal models. Applications must demonstrate how the proposed resources and technologies impact rigor and reproducibility of animal studies.